Local drugmaker HUYA Bioscience International inked a licensing deal with Eisai worth up to $280 million-plus, the company announced Monday.
HUYA granted the Japanese pharma an exclusive license to its anti-cancer compound, HBI-8000, in eight Asian nations: Indonesia, Japan, Malaysia, the Philippines, Singapore, South Korea, Thailand, and Vietnam.
“The license reinforces our vision of leveraging clinical data generated within Asia using the Tripartite Cooperation Treaty to expand into other countries, such as Japan and Korea,” Mireille Gillings, HUYA’s president, CEO, and executive chairman, said in a statement. “Eisai's global strength in oncology will help ensure the drug's path to regulatory approval.”
HBI-8000 is approved in China, where it is marketed under the name Chidamide as a treatment for T-cell non-Hodgkin’s lymphomas. HBI-8000 is in Phase I development for non-Hodgkin's lymphoma (NHL) in Japan, where HUYA intends to complete development for commercialization by Eisai.
Eisai will hold exclusive rights to develop future indications, such as solid tumors, there and in the other territories covered by the license agreement.
In return, Eisai agreed to pay HUYA upfront and potential milestone payments totaling up to $280 million, plus royalties on net sales. HUYA agreed to manufacture and supply the product to Eisai for commercialization and other future development.